Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Reduced prevalence of SARS-CoV-2 infection in ABO blood group O

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Incidence and impact of parvovirus B19 infection in seronegative solid organ transplant recipients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Neprilysin inhibition increases glucagon levels in humans and mice with potential effects on amino acid metabolism

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Recently, reports of severe thromboses, thrombocytopenia, and hemorrhage in persons vaccinated with the chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19, AZD1222, Vaxzevria; Oxford/AstraZeneca) against severe acute respiratory syndrome coronavirus 2 have emerged. We describe an otherwise healthy 30-year-old woman who developed thrombocytopenia, ecchymosis, portal vein thrombosis, and cerebral venous sinus thrombosis the second week after she received the ChAdOx1 nCoV-19 vaccine. Extensive diagnostic workup for thrombosis predispositions showed heterozygosity for the prothrombin mutation, but no evidence of myeloproliferative neoplasia or infectious or autoimmune diseases. Her only temporary risk factor was long-term use of oral contraceptive pills (OCPs). Although both the prothrombin mutation and use of OCPs predispose to portal and cerebral vein thrombosis, the occurrence of multiple thromboses within a short time and the associated pattern of thrombocytopenia and consumption coagulopathy are highly unusual. A maximum 4T heparin-induced thrombocytopenia (HIT) score and a positive immunoassay for anti-platelet factor 4/heparin antibodies identified autoimmune HIT as a potential pathogenic mechanism. Although causality has not been established, our case emphasizes the importance of clinical awareness. Further studies of this potentially new clinical entity have suggested that it should be regarded as a vaccine-induced immune thrombotic thrombocytopenia.

OriginalsprogEngelsk
TidsskriftBlood advances
Vol/bind5
Udgave nummer12
Sider (fra-til)2569-2574
Antal sider6
ISSN2473-9529
DOI
StatusUdgivet - 22 jun. 2021

ID: 66399024